



DHBNZ Safe and Quality Use of  
Medicines Group (SQM group)  
c/o HQSC  
Ministry of Health  
Private Bag 92 522  
Auckland

22 July 2011

To whom it may concern

**Re: Urgent SQM alert: Acute haemorrhage associated with dabigatran leading to hospital admissions in New Zealand**

Patients have been admitted to hospital for treatment of bleeding following dabigatran initiation. This alert contains important information on the patient parameters that are required to be considered before dabigatran initiation. There is also information that patients have to know when they are started on dabigatran and this is listed on the reverse of the alert.

PHARMAC have produced guidelines for hospitals for treating bleeding episodes associated with dabigatran treatment. Please discuss with your local haematologist if you have a patient with a bleeding episode treated in primary care.

The alert has been sent to pharmacy facilitators, clinical leaders in PHO's, medicines advisory/medicine safety committees in hospitals and DHB funding and planning managers for distribution to community pharmacies.

Kind Regards

Beth Loe  
National Coordinator  
Safe and Quality Use of Medicines Group  
Ph 09 580 9160  
email [beth.loe@hqsc.govt.nz](mailto:beth.loe@hqsc.govt.nz)